Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients
Sabine Hazan, Sonya Dave, Anoja W Gunaratne, Sibasish Dolai, Robert L Clancy, Peter A Mccullough, Thomas J Borody
Future Microbiology, doi:10.2217/fmb-2022-0014
Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for Helicobacter pylori, the authors present a highly effective COVID-19 therapeutic combination, stemming from clinical observations. Patients & methods: In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C. Results & conclusions: All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p < 0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms. Clinical Trial Registration: NCT04949230 (ClinicalTrial.gov)
Conclusion This study builds on extensive literature to provide practical, inexpensive, safe, readily available and highly effective IVM triple therapy aiming to prevent resistance and one that can confidently be used as a routine treatment for outpatient COVID-19.
Summary points • The authors observed the effectiveness of a novel combination of ivermectin, doxycycline, zinc and vitamins D and C in 24 COVID-positive subjects with high-risk features/comorbidities. • The majority of the subjects were hypoxic (23 out of 24; oxygen saturation [SpO 2 ] <90%), with 4 below SpO 2 <85% on presentation. Many subjects had related comorbidities (n = 11; 45.8%). The median age of all subjects was 66 years old. • Intervention consisted of 10 days of doxycycline (100 mg twice a day), ivermectin (12 mg on day 1, day 4 and day 8), zinc (25 mg twice a day), vitamin D3 (1500 IU twice a day) and vitamin C (1500 mg twice a day). All treatment was given orally and ceased at the end of 10 days. • One hundred percent of patients accepting treatment survived without the need for hospitalization. All subjects recovered from hypoxic symptoms (SpO 2 >95%) within 10 days of treatment. • The authors report an effective and inexpensive COVID therapy preventing hospitalization and death in all patients and rapid resolution of hypoxia in these ambulatory 'moderately to severely' ill patients.
Supplementary data To view the supplementary data that accompany this paper please visit the journal..
References
Ashraf, Gue, Baddour, Case report: strongyloidiasis refractory to treatment with ivermectin, Am. J. Med. Sci
At, Karim, Islam, Guo, He, A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients, Research Square
Bryant, Lawrie, Dowswell, Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines, Am. J. Ther
Butler, Yu, Dorward, Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial, Lancet Respir. Med
Campbell, History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents, Curr. Pharm. Biotechnol
Chaccour, Casellas, Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial, EClinicalMedicine
Crump, Omura, Ivermectin, 'wonder drug' from Japan: the human use perspective, Proc. Jpn Acad. Ser. B Phys. Biol. Sci
Guzzo, Furtek, Porras, Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J. Clin. Pharmacol
Ha, Am, Df, Kk, As, Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad Iraq,
doi:10.1101/2020.10.26.20219345Jans, Wagstaff, Ivermectin as a broad-spectrum host-directed antiviral: the real deal?, Cells
Krolewiecki, Lifschitz, Moragas, Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial, EClinicalMedicine
Lange, Triple combinations: present and future, J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol
Lopez-Medina, Lopez, Hurtado, Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial, JAMA
Mahmud, Rahman, Alam, Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial, J. Int. Med. Res
Mccullough, Alexander, Armstrong, Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19), Rev. Cardiovasc. Med
Mejia, Medina, Cornejo, Oxygen saturation as a predictor of mortality in hospitalized adult patients with COVID-19 in a public hospital in Lima, Peru, PLoS ONE
Mounsey, Holt, Mccarthy, Currie, Walton, Longitudinal evidence of increasing in vitro tolerance of scabies mites to ivermectin in scabies-endemic communities, Arch. Dermatol
Munoz, Ballester, Antonijoan, Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers, PLoS Negl. Trop. Dis
Navarro, Camprubi, Requena-Mendez, Safety of high-dose ivermectin: a systematic review and meta-analysis, J. Antimicrob. Chemother
Ohe, Furuya, Goudarzi, Multidrug treatment for COVID-19, Drug. Discov. Ther
Okumus, Demirturk, Cetinkaya, Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients, BMC Infect. Dis
Procter, Ross, Pickard, Smith, Hanson et al., Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection, Rev. Cardiovasc. Med
Re, Brepe, Terranova, Es, Cluster randomised trials -ivermectin repurposing for COVID-19 treatment of outpatients with mild disease in primary health care centers, Research Square,
doi:10.21203/rs.3.rs-495945/v1(2021Samad, Sodunke, Abubakar, The implications of zinc therapy in combating the COVID-19 global pandemic, J. Inflamm. Res
Samaha, Mouawia, Fawaz, Effects of a single dose of ivermectin on viral and clinical outcomes in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in Lebanon, Viruses
Shahbaznejad, Davoudi, Eslami, Effects of ivermectin in patients with COVID-19: a multicenter, double-blind, randomized, controlled clinical trial, Clin. Ther
Shikiya, Zaha, Niimura, Clinical study of eradicated and resistant patients to treatment with ivermectin for strongyloidiasis
Shikiya, Zaha, Niimura, Clinical study on ivermectin against 125 strongyloidiasis patients
Shoop, Ivermectin resistance, Parasitol. Today
Velthuis, Van Den Worm, Sims, Baric, Snijder et al., Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture, PLoS Pathog
Ventz, Lai, Cloughesy, Wen, Trippa et al., Design and evaluation of an external control arm using prior clinical trials and real-world data, Clin. Cancer Res
Yagisawa, Hanaki, Ōmura, Global trends in clinical studies of ivermectin in COVID-19, J. Antibiot
Zaidi, Dehgani-Mobaraki, Retracted article: the mechanisms of action of Ivermectin against SARS-CoV-2: an evidence-based clinical review article, J. Antibiot,
doi:10.1038/s41429-021-00430-5Zithromax R, azithromycin tablets) and (azithromycin for oral suspension
{ 'indexed': {'date-parts': [[2024, 4, 8]], 'date-time': '2024-04-08T20:30:27Z', 'timestamp': 1712608227696},
'reference-count': 42,
'publisher': 'Informa UK Limited',
'issue': '5',
'funder': [{'name': 'ProgenaBiome, LLC'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2022, 3]]},
'abstract': '<jats:p> Aims: Ivermectin is a safe, inexpensive and effective early COVID-19 treatment '
'validated in 20+ random, controlled trials. Having developed combination therapies for '
'Helicobacter pylori, the authors present a highly effective COVID-19 therapeutic combination, '
'stemming from clinical observations. Patients & methods: In 24 COVID-19 subjects refusing '
'hospitalization with high-risk features, hypoxia and untreated moderate to\xa0severe symptoms '
'averaging 9\xa0days, the authors administered this novel combination of ivermectin, '
'doxycycline, zinc and vitamins D and C. Results & conclusions: All subjects resolved '
'symptoms (in 11\xa0days on average), and oxygen saturation improved in 24\xa0h (87.4% to '
'93.1%; p\xa0=\xa00.001). There were no hospitalizations or deaths, less than (p\xa0<\xa0'
'0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination '
'therapy is safe and effective even when used in outpatients with moderate to\xa0severe '
'symptoms. </jats:p><jats:p> Clinical Trial Registration: NCT04482686 ( ClinicalTrial.gov ) '
'</jats:p>',
'DOI': '10.2217/fmb-2022-0014',
'type': 'journal-article',
'created': {'date-parts': [[2022, 2, 9]], 'date-time': '2022-02-09T08:40:49Z', 'timestamp': 1644396049000},
'page': '339-350',
'source': 'Crossref',
'is-referenced-by-count': 20,
'title': 'Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 '
'patients',
'prefix': '10.2217',
'volume': '17',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-6592-3776',
'authenticated-orcid': False,
'given': 'Sabine',
'family': 'Hazan',
'sequence': 'first',
'affiliation': [{'name': 'ProgenaBiome, LLC, 1845 Knoll Dr., Ventura, CA 93003, USA'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-7653-0388',
'authenticated-orcid': False,
'given': 'Sonya',
'family': 'Dave',
'sequence': 'additional',
'affiliation': [ { 'name': 'North End Advisory, 2451 Cumberland Pkwy SE Ste. 3152, Atlanta, '
'GA 30339, USA'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-6767-614X',
'authenticated-orcid': False,
'given': 'Anoja W',
'family': 'Gunaratne',
'sequence': 'additional',
'affiliation': [ { 'name': 'Centre for Digestive Diseases, 229 Great North Road, Five Dock, '
'NSW, 2046, Australia'}]},
{ 'given': 'Sibasish',
'family': 'Dolai',
'sequence': 'additional',
'affiliation': [ { 'name': 'Centre for Digestive Diseases, 229 Great North Road, Five Dock, '
'NSW, 2046, Australia'}]},
{ 'given': 'Robert L',
'family': 'Clancy',
'sequence': 'additional',
'affiliation': [ { 'name': 'Centre for Digestive Diseases, 229 Great North Road, Five Dock, '
'NSW, 2046, Australia'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-0997-6355',
'authenticated-orcid': False,
'given': 'Peter A',
'family': 'McCullough',
'sequence': 'additional',
'affiliation': [{'name': 'Truth for Health Foundation, Tucson, AZ 85728, USA'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-0519-4698',
'authenticated-orcid': False,
'given': 'Thomas J',
'family': 'Borody',
'sequence': 'additional',
'affiliation': [ { 'name': 'Centre for Digestive Diseases, 229 Great North Road, Five Dock, '
'NSW, 2046, Australia'}]}],
'member': '301',
'reference': [ {'key': 'B1', 'doi-asserted-by': 'publisher', 'DOI': '10.31083/j.rcm.2020.04.264'},
{'key': 'B2', 'doi-asserted-by': 'publisher', 'DOI': '10.2174/138920112800399095'},
{'key': 'B3', 'doi-asserted-by': 'publisher', 'DOI': '10.2183/pjab.87.13'},
{ 'issue': '1',
'key': 'B4',
'first-page': '44',
'volume': '74',
'author': 'Yagisawa MFP',
'year': '2021',
'journal-title': 'J. Antibiot.'},
{'key': 'B5', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/MJT.0000000000001402'},
{'key': 'B6', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.eclinm.2020.100720'},
{'key': 'B7', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/03000605211013550'},
{'key': 'B8', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s12879-021-06104-9'},
{'key': 'B9', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/v13060989'},
{'key': 'B10', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.clinthera.2021.04.007'},
{'key': 'B11', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/jac/dkz524'},
{'key': 'B12', 'doi-asserted-by': 'publisher', 'DOI': '10.1177/009127002401382731'},
{'key': 'B13', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2021.3071'},
{'key': 'B14', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.eclinm.2021.100959'},
{'key': 'B15', 'doi-asserted-by': 'publisher', 'DOI': '10.31083/j.rcm.2020.04.260'},
{ 'key': 'B16',
'author': 'Zaidi AK',
'year': '2021',
'journal-title': 'J. Antibiot. (Tokyo)'},
{'key': 'B17', 'author': 'Chahla Re MT', 'year': '2021', 'journal-title': 'Research Square'},
{'key': 'B18', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/00042560-199510001-00016'},
{'key': 'B19', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0244171'},
{ 'key': 'B20',
'unstructured': 'Center for Disease Control. COVID-19 case surveillance public use data '
'with geography. '
'https://data.cdc.gov/Case-Surveillance/COVID-19-Case-Surveillance-Public-Use-Data-with-Ge/n8mc-b4w4'},
{ 'key': 'B21',
'unstructured': 'Center for Disease Control. People with certain medical conditions. '
'https://data.cdc.gov/Case-Surveillance/COVID-19-Case-Surveillance-Public-Use-Data-with-Ge/n8mc-b4w4'},
{ 'key': 'B22',
'unstructured': 'Food and Drug Administration. STROMECTOL® (IVERMECTIN). '
'https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050742s022lbl.pdf'},
{'key': 'B23', 'doi-asserted-by': 'publisher', 'DOI': '10.1158/1078-0432.CCR-19-0820'},
{'key': 'B24', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/0169-4758(93)90136-4'},
{ 'issue': '4',
'key': 'B25',
'first-page': '178',
'volume': '311',
'author': 'Ashraf M',
'year': '1996',
'journal-title': 'Am. J. Med. Sci.'},
{ 'key': 'B26',
'doi-asserted-by': 'publisher',
'DOI': '10.11150/kansenshogakuzasshi1970.66.935'},
{ 'key': 'B27',
'doi-asserted-by': 'publisher',
'DOI': '10.11150/kansenshogakuzasshi1970.68.13'},
{'key': 'B28', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/archdermatol.2009.125'},
{ 'key': 'B29',
'author': 'Mohammed At CM',
'year': '2020',
'journal-title': 'Research Square'},
{ 'key': 'B30',
'unstructured': 'A combination of ivermectin and doxycycline possibly blocks the viral '
'entry and modulate the innate immune response in COVID-19 patients. '
'https://chemrxiv.org/engage/chemrxiv/article-details/60c74d85842e655304db34b6'},
{'key': 'B31', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S2213-2600(21)00310-6'},
{'key': 'B32', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.ppat.1001176'},
{'key': 'B33', 'doi-asserted-by': 'publisher', 'DOI': '10.2147/JIR.S295377'},
{'key': 'B34', 'author': 'Hashim Ha MM', 'year': '2020', 'journal-title': 'medRxiv'},
{ 'key': 'B35',
'unstructured': 'Drug Interactions Checker - Medscape Drug Reference Database (2021). '
'https://reference.medscape.com/drug-interactionchecker'},
{ 'key': 'B36',
'unstructured': 'ZITHROMAX® (azithromycin tablets) and (azithromycin for oral '
'suspension). '
'https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050710s039,050711s036,050784s023lbl.pdf'},
{ 'key': 'B37',
'unstructured': 'Center for Drug Evaluation and Research. Approval package for: Galzin '
'capsules. '
'https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020458ap.pdf'},
{ 'key': 'B38',
'unstructured': 'Food and Drug Administration. Highlights of prescribing information, '
'doxycycline hyclate. '
'https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/90431Orig1s010lbl.pdf'},
{'key': 'B39', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/cells9092100'},
{'key': 'B40', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pntd.0006020'},
{'key': 'B41', 'doi-asserted-by': 'publisher', 'DOI': '10.5582/ddt.2021.01005'},
{ 'key': 'B42',
'unstructured': 'Front Line COVID-19 Critical Care Alliance. Ivermectin reduces the risk '
'of death from COVID-19 – a rapid review and meta-analysis in support of '
'the recommendation of the Front Line COVID-19 Critical Care Alliance. '
'https://b3d2650e-e929-4448-a527-4eeb59304c7f.filesusr.com/ugd/593c4f_8cb655bd21b1448ba6cf1f4c59f0d73d.pdf'}],
'container-title': 'Future Microbiology',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.futuremedicine.com/doi/pdf/10.2217/fmb-2022-0014',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 3, 4]],
'date-time': '2022-03-04T15:16:41Z',
'timestamp': 1646407001000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.futuremedicine.com/doi/10.2217/fmb-2022-0014'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 3]]},
'references-count': 42,
'journal-issue': {'issue': '5', 'published-print': {'date-parts': [[2022, 3]]}},
'alternative-id': ['10.2217/fmb-2022-0014'],
'URL': 'http://dx.doi.org/10.2217/fmb-2022-0014',
'relation': { 'has-preprint': [ { 'id-type': 'doi',
'id': '10.1101/2021.07.06.21259924',
'asserted-by': 'object'}]},
'ISSN': ['1746-0913', '1746-0921'],
'subject': ['Microbiology (medical)', 'Microbiology'],
'container-title-short': 'Future Microbiology',
'published': {'date-parts': [[2022, 3]]}}
